Organization shortlisted in “Best Contract Research Organizations – Full-Service Providers Category”
Morrisville, NC – Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global CRO, was announced as a finalist for the third year in the 2018 Scrip Awards’ “Best Contract Research Organization – Full-Service Providers” category. The winners will be announced today at the Scrip Awards 2018 ceremony in London.
Acknowledging the critical role that CROs play in drug development, a panel of 17 judges selected finalists based on the quality of services and relationships they have built with their clients. Selection criteria included special emphasis on the innovative patient recruitment strategies the CRO carried into each partnership.
Now in its 14th year, the Scrip Awards offer the pharmaceutical and biotech industries with an opportunity to acknowledge its highest achievers across all parts of the value chain, and to recognize both corporate and individual achievement.
For further information about Worldwide Clinical Trials, please visit Worldwide.com.
Connect with Worldwide Clinical Trials:
- Tweet: @Worldwidetrials shortlisted as a 2018 #ScripAward “Best #CRO – Full-Service Providers” finalist for its ongoing work as an #UncommonCRO
- Follow us on Twitter: @worldwidetrials
- Find us on LinkedIn: https://www.linkedin.com/company/worldwide-clinical-trials-inc-
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, immune-mediated inflammatory disorders (IMID), oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit https://www.worldwide.com.
